Soligenix, Inc. (SNGX)
| Market Cap | 19.94M |
| Revenue (ttm) | 858,496 |
| Net Income (ttm) | -14.75M |
| Shares Out | 43.34M |
| EPS (ttm) | -0.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 173,985 |
| Open | 0.457 |
| Previous Close | 0.452 |
| Day's Range | 0.432 - 0.480 |
| 52-Week Range | 0.380 - 1.000 |
| Beta | 1.75 |
| Analysts | Buy |
| Price Target | 4.21 (+815.02%) |
| Earnings Date | Mar 27, 2023 |
About SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflamm... [Read more]
Financial Performance
In 2021, Soligenix's revenue was $824,268, a decrease of -65.07% compared to the previous year's $2.36 million. Losses were -$12.55 million, -29.04% less than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for SNGX stock is "Buy." The 12-month stock price forecast is $4.21, which is an increase of 815.02% from the latest price.
News
Soligenix Invited to Present at the Virtual Investor Summit Event
Focusing on 25 micro-cap companies with key catalysts and/or strong performance in the current market PRINCETON, N.J. , Jan. 19, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the C...
Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
PRINCETON, N.J. , Dec. 23, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge
RiVax ® - Vaccinated NHP survival was statistically significantly correlated with an epitope-specific serum assay ("EPICC") prior to challenge Correlates of protection are essential to support approva...
Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis
Study HPN-PSR-01 opens patient enrollment PRINCETON, N.J. , Dec. 19, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on d...
7 Stocks to Add to Your 10x Watchlist
There are few things that get growth investors excited like the opportunity to invest in 10x stocks. By definition, these 10x stocks (also referred to as 10 baggers) can add huge gains to your portfol...
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J. , Dec. 15, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
PRINCETON, N.J. , Nov. 15, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference
Princeton, New Jersey--(Newsfile Corp. - November 11, 2022) - Investor Summit Group, today announced that Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company) will attend the Q4 Investor Summit l...
Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results
PRINCETON, N.J. , Nov. 10, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
Emerging infectious diseases where n o protective vaccines are currently available SuVax™ targets Sudan ebolavirus, origin of a current disease outbreak in Uganda PRINCETON, N.J. , Oct. 27, 2022 /PRNe...
Soligenix Announces Formation of Psoriasis Medical Advisory Board
Phase 2a clinical study in mild-to-moderate psoriasis initiating in December 2022 PRINCETON, N.J. , Oct. 25, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-sta...
Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting
Meeting adjourned to November 17, 2022, at 9:00 a.m., Eastern Time Soligenix encourages all stockholders as of record July 25, 2022, who have not yet voted, to vote by 11:59 p.m.
Soligenix Enters Q4 With Multiple Catalysts in Play
New York, New York--(Newsfile Corp. - October 13, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX) is anticipating significant catalysts in Q4 and a potentia...
Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
- Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time - Soligenix encourages all stockholders of record at the close of business on July 25, 2022 who have not yet voted, to vote by 11:59...
FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL
New York, New York--(Newsfile Corp. - September 12, 2022) - PCG Digital -- Late-stage biopharmaceutical company Soligenix, Inc. (NASDAQ: SNGX) has announced the award of a $2.6 million grant from the ...
Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PRINCETON, N.J. , Sept. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Grant supports study of expanded HyBryte™ treatment, including in the Home Use Setting PRINCETON, N.J. , Sept. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late...
Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results
PRINCETON, N.J. , Aug. 12, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J. , July 27, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients
HyBryte(TM) NDA Anticipated in H2 2022New York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX), has completed the larg...
Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen
SERB Pharmaceuticals pursuing therapeutic treatment against ricin poisoning using Soligenix ricin antigen PRINCETON, N.J. , July 25, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or ...
Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study
Soligenix Inc (NASDAQ: SNGX) announced the results of its Phase 3 FLASH study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL) had been published in the Journal of the Ame...
HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology
Published findings demonstrate that HyBryte™ treatment statistically significantly reduced CTCL lesion size HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL PRINCETON,...
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
Enrollment on Track to Begin in 4th Quarter of 2022 PRINCETON, N.J. , June 28, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company ...
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
Bivalent vaccine provides 100% protection in non-human primates against both Sudan ebolavirus and Marburg marburgvirus Only subunit (protein) vaccine platform shown to protect against potentially leth...